Recombinant Anti-CD64 x Anti-HER2 Bispecific Antibody (Bi-nanobody) is designed to be expressed as a VHH from anti-CD64 antibody variable domains fused with a VHH from an anti-HER2 antibody variable domains. It contains a His-tag at the C/N terminus for affinity purification. The BsAb exits as monomer in reducing and non-reducing conditions. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Breast cancer; Gastric cancer; Prostate cacncer; Ovarian cancer; Solid tumors therapy.